Infection vs Inflammation: The Bronchiectasis "Tug Of War"

Abstract

Competing Interests: Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: S. H. C. has served on advisory boards for CSL Behring, Pneumagen Ltd. and Boehringer Ingelheim, has served on Data Safety and Monitoring Boards (DSMB) for Inovio Pharmaceuticals Ltd and Imam Abdulrahman Bin Faisal University and received lecture fees from Astra-Zeneca and Chiesi Farmaceutici, all outside of the submitted work. A. B. C. report grants from the National Health and Medical Research Council (NHMRC) and NHMRC managed grants (MRFF) and received fees to the institution for independent data management committee member for clinical trials for Moderna (COVID-19 and EBV vaccines) and of an unlicensed vaccine (GlaxoSmithKline), and monoclonal antibody (AstraZeneca), consulting on study designs for Zambon and Boehringer Ingelheim, and personal fees for being an author of two UpToDate chapters. J. D. C. reports grants or contracts from Grifols; consulting fees from Antabio, AstraZeneca, Boehringer Ingelheim, Chiesi, Glaxosmithkline, Grifols, Insmed, Janssen, Novartis, Pfizer, and Zambon; and leadership or fiduciary roles as Chair of European Respiratory Society (ERS) Bronchiectasis Guideline Task Force, Chief Editor of European Respiratory Journal, and Chair of EMBARC Clinical Research Collaboration.